Bio-Connect
TDZD-8 [327036-89-5]

TDZD-8 [327036-89-5]

Research Use Only
AG-CR1-3740
AdipoGen Life Sciences
CAS Number327036-89-5
Product group Chemicals
Estimated Purity>98%
Molecular Weight222.3
Price on request
Packing Size
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    TDZD-8 [327036-89-5]
  • Delivery Days Customer
    10
  • CAS Number
    327036-89-5
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Danger,Non-hazardous
  • Molecular Formula
    C10H10N2O2S
  • Molecular Weight
    222.3
  • Scientific Description
    Chemical. CAS: 327036-89-5. Formula: C10H10N2O2S. MW: 222.3. TDZD-8 is a non-ATP competitive selective inhibitor of the serine/threonine kinase glycogen synthase kinase 3beta (GSK3beta; IC50 = 2microM), binding to the active site of GSK3beta. It does not significantly affect the activities of Cdk-1/cyclin B, CK-II, cAMP-dependent protein kinase or protein kinase C (IC50s = >100 microM), but inhibits PKC and Flt-3 activities (IC50 = 1.4-5.5microM and 673nM, respectively). TDZD-8 has been used to study the role of GSK3beta during stem cell differentiation as well as in cell and animal models of Alzheimers disease and other neurodegenerative disorders. TDZD-8 is a potent anti-proliferative and pro-apoptotic agent of glioma cells in vitro and in vivo. These effects are associated with an early activation of extracellular signal-regulated kinase (ERK), which is followed by an increased expression of the early growth response-1 (EGR-1) and p21. TDZD-8 potentially inhibits the 33.8-kDa Main protease (Mpro)/3C-like protease of SARS-CoV-2, consequently inhibiting viral transcription and replication and possibly inhibiting spread of COVID-19. - TDZD-8 is a non-ATP competitive selective inhibitor of the serine/threonine kinase glycogen synthase kinase 3beta (GSK3beta; IC50 = 2microM), binding to the active site of GSK3beta. It does not significantly affect the activities of Cdk-1/cyclin B, CK-II, cAMP-dependent protein kinase or protein kinase C (IC50s = >100 microM), but inhibits PKC and Flt-3 activities (IC50 = 1.4-5.5microM and 673nM, respectively). TDZD-8 has been used to study the role of GSK3beta during stem cell differentiation as well as in cell and animal models of Alzheimers disease and other neurodegenerative disorders. TDZD-8 is a potent anti-proliferative and pro-apoptotic agent of glioma cells in vitro and in vivo. These effects are associated with an early activation of extracellular signal-regulated kinase (ERK), which is followed by an increased expression of the early growth response-1 (EGR-1) and p21. TDZD-8 potentially inhibits the 33.8-kDa Main protease (Mpro)/3C-like protease of SARS-CoV-2, consequently inhibiting viral transcription and replication and possibly inhibiting spread of COVID-19.
  • SMILES
    O=C(N1CC2=CC=CC=C2)N(C)SC1=O
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200